Research map: Effect of neoadjuvant chemotherapy on [68Ga]Ga-FAPI-46 PET/CT in peritoneal carcinomatosis: a prospective translational exploratory sub-cohort analysis

Back to the article

Papers in this map

  1. 68 Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer · Clemens Kratochwil · 2019 · 1508 citations · Cited by this paper
  2. Real-world evaluation of [177Lu]Lu-PSMA-617 RLT in post-taxane mCRPC: feasibility and safety of individualized treatment in a challenging cohort · 2026 · Related
  3. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial · François Quénet · 2021 · 829 citations · Cited by this paper
  4. Whole-body TSPO-PET reveals stage-dependent disruption of systemic immune organ interactions in glioblastoma · 2026 · Related
  5. The role of fibroblast activation protein in health and malignancy · Allison A. Fitzgerald · 2020 · 618 citations · Cited by this paper
  6. Evaluation of treatment efficacy of the 161Tb- and 177Lu-Labeled GRPR antagonists AMTG and RM2 in a mouse model of prostate cancer · 2026 · Related
  7. ESGO–ESMO–ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease · Jonathan A. Ledermann · 2024 · 328 citations · Cited by this paper
  8. From image reconstruction to clinical prognosis: A comprehensive analysis of centiloid-based amyloid PET assessment · 2026 · Related
  9. Chemotherapy Response Score: Development and Validation of a System to Quantify Histopathologic Response to Neoadjuvant Chemotherapy in Tubo-Ovarian High-Grade Serous Carcinoma · Steffen Böhm · 2015 · 312 citations · Cited by this paper
  10. [18F]FDG PET during immunotherapy: mind the gap between evidence, imaging guidelines, and oncology practice · 2026 · Related
  11. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in patients with advanced ovarian cancer (OVHIPEC-1): final survival analysis of a randomised, controlled, phase 3 trial · S. Lot Aronson · 2023 · 136 citations · Cited by this paper
  12. CSF proteomic pathway alterations and caudate dopamine transporter deficits predict cognitive vulnerability in early Parkinson’s disease · 2026 · Related
  13. Tumor microenvironment in ovarian cancer peritoneal metastasis · Shuangshuang Mei · 2023 · 113 citations · Cited by this paper
  14. Skeletal muscle radiodensity as an automated survival predictor in men with metastatic castration-resistant prostate cancer undergoing PSMA-targeted radioligand therapy · 2026 · Related
  15. Clinical applications of fibroblast activation protein inhibitor positron emission tomography (FAPI-PET) · Yuriko Mori · 2024 · 107 citations · Cited by this paper
  16. In vivo multimodal PET/MRI imaging and plasma biomarkers implicate glymphatic dysfunction linking neuroinflammation to tau pathology in the early Alzheimer’s disease continuum · 2026 · Related
  17. FAPI-avid nonmalignant PET/CT findings: An expedited systematic review · Morten Bentestuen · 2023 · 99 citations · Cited by this paper
  18. Prospective comparison of [68Ga]Ga-FAPI-04 PET/MRI, [18F]FDG PET/CT, and contrast-enhanced MRI for predicting pathologic complete response after neoadjuvant chemotherapy in breast cancer · 2026 · Related
  19. Use of 18 F-FDG PET/CT in the preoperative evaluation of patients diagnosed with peritoneal carcinomatosis of ovarian origin, candidates to cytoreduction and hipec. A pending issue · Víctor López‐López · 2016 · 73 citations · Cited by this paper
  20. Head-To-Head Comparison of 68Ga-FAPI PET/CT and FDG PET/CT for the Detection of Peritoneal Metastases: Systematic Review and Meta-Analysis · Gege Zhao · 2022 · 58 citations · Cited by this paper
  21. Residual ANTXR1+ myofibroblasts after chemotherapy inhibit anti-tumor immunity via YAP1 signaling pathway · Monika Licaj · 2024 · 58 citations · Cited by this paper
  22. 18F-FDG-PET/CT can identify histopathological non-responders to platinum-based neoadjuvant chemotherapy in advanced epithelial ovarian cancer · Tuulia Vallius · 2015 · 57 citations · Cited by this paper
  23. [68Ga]Ga-FAPI-46 PET accuracy for cancer imaging with histopathology validation: a single-centre, single-arm, interventional, phase 2 trial · Kim Magaly Pabst · 2025 · 51 citations · Cited by this paper
  24. 18F-FDG-PET/CT based total metabolic tumor volume change during neoadjuvant chemotherapy predicts outcome in advanced epithelial ovarian cancer · Tuulia Vallius · 2018 · 45 citations · Cited by this paper
  25. Initial Results of 68 Ga-FAPI-46 PET/MRI to Assess Response to Neoadjuvant Chemotherapy in Breast Cancer · Philipp Backhaus · 2022 · 44 citations · Cited by this paper
  26. A comparative study of [68Ga]Ga-FAPI-04 PET/MR and [18F]FDG PET/CT in the diagnostic accuracy and resectability prediction of ovarian cancer · Yun Xi · 2023 · 40 citations · Cited by this paper
  27. Metastasis-associated fibroblasts in peritoneal surface malignancies · Cristiano Ramos · 2024 · 40 citations · Cited by this paper
  28. 68Ga-Labeled Fibroblast Activation Protein Inhibitor PET/CT for the Early and Late Prediction of Pathologic Response to Neoadjuvant Chemotherapy in Breast Cancer Patients: A Prospective Study · Ling Chen · 2023 · 35 citations · Cited by this paper
  29. Imaging Evaluation of Peritoneal Metastasis: Current and Promising Techniques · Chen Fu · 2024 · 30 citations · Cited by this paper
  30. Imaging of Peritoneal Metastases in Ovarian Cancer Using MDCT, MRI, and FDG PET/CT: A Systematic Review and Meta-Analysis · Athina C. Tsili · 2024 · 28 citations · Cited by this paper
  31. Value of68Ga-FAPI-04 and18F-FDG PET/CT in Early Prediction of Pathologic Response to Neoadjuvant Chemotherapy in Locally Advanced Gastric Cancer · Ying Miao · 2023 · 25 citations · Cited by this paper
  32. Distribution of residual disease in the peritoneum following neoadjuvant chemotherapy in advanced epithelial ovarian cancer and its potential therapeutic implications · Aditi Bhatt · 2020 · 19 citations · Cited by this paper
  33. Surgical evidence-based comparison of [68Ga]Ga-FAPI-04 PET and MRI-DWI for assisting debulking surgery in ovarian cancer patients · Xiang Li · 2024 · 13 citations · Cited by this paper
  34. [18F]AlF-NOTA-FAPI-04 PET/CT for Predicting Pathologic Response of Resectable Esophageal Squamous Cell Carcinoma to Neoadjuvant Camrelizumab and Chemotherapy: A Phase II Clinical Trial · Yinjun Dong · 2024 · 11 citations · Cited by this paper
  35. Integrated 68Ga-FAPI-04 PET/MR in Pancreatic Cancer · Zeyu Zhang · 2024 · 10 citations · Cited by this paper
  36. Characteristics of 18F-FAPI-04 PET/CT in patients with peritoneal metastasis and to predict treatment efficacy, a head-to-head comparison with 18F-FDG PET/CT · Yafei Zhang · 2025 · 10 citations · Cited by this paper
  37. Early Assessment of Response to Neoadjuvant Chemotherapy with 18F-FDG-PET/CT in Patients with Advanced-Stage Ovarian Cancer · Young Shin Chung · 2020 · 9 citations · Cited by this paper
  38. 68Ga-DOTA-FAPI-04 and 18F-FDG PET/CT: a head-to-head comparison for peritoneal carcinomatosis diagnostic accuracy · Xiaolin Chen · 2025 · 9 citations · Cited by this paper
  39. CT and MR in peritoneal malignancies: pearls and pitfalls at preoperative examination · Michela Polici · 2025 · 7 citations · Cited by this paper

Source: OpenAlex (CC0)